| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28a869d6fc950d50f6df03f549ca3afa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-806 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-08 |
| filingDate |
1979-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1980-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
FR-2445149-A1 |
| titleOfInvention |
PHARMACEUTICAL COMPOSITION HAVING ANTI-TUMOR ACTIVITY |
| abstract |
The present invention relates to a pharmacological composition having an antitumor activity. It consists of an anti-tumor substance having at least one amino or carboxyl group linked by an amide bond to an anti-tumor antibody purified by affinity chromatography. This pharmacological composition does not give rise to side effects, such as pyrexia or anaphylaxis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0122132-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0063988-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2584293-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2504010-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2548901-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0122132-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0208615-A1 |
| priorityDate |
1978-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |